Quiflapon sodium (MK-591) is a selective and specific FLAP inhibitor and a potent, orally active inhibitor of leukotriene biosynthesis; it induces apoptosis in various cell types, including prostate cancer cells, without inhibiting PI3K-Akt or ERK pathways; it blocks SEB-induced human PBMC proliferation and downregulates SEB-upregulated genes (cathepsin L, IL-17, and GBP-2); it activates stress kinase JNK, contributing to apoptosis; it exhibits synergistic pro-apoptotic effects with LY294002 in prostate cancer cells; it ameliorates hyperoxia-induced aberrant alveolarization in mice; it reduces amyloid-beta burden and brain IL-1β levels in mouse models; it decreases total CREB and phosphorylated CREB (Ser133) levels in the brain.